8月7日，Twist Bioscience盘中下跌5.1%，报109.13美元/股，成交额1.2亿美元。消息面上，公司此前公布财年第三季度业绩呈现明显分化：营收录得1.184亿美元，同比增长23.2%，超出预期；但每股亏损0.56美元，较去年同期每股盈利0.33美元大幅恶化，且不及市场预期。公司上调全年营收指引至4.56亿至4.57亿美元，Q4营收指引1.23亿至1.24亿美元，均大幅高于一致预期的1.174亿美元。
财报发布后股价经历剧烈多空博弈，8月3日一度下跌逾9%，随后因强劲营收指引反弹超6%。当前回调或反映市场在消化高估值与盈利恶化之间的持续博弈，此前Evercore ISI已于7月将公司评级下调至"与大市持平"。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.